Table 1.

The baseline clinical characteristics and medical therapies of patients with non-reserved and reserved right ventricular (RV) function post mitral valve (MV) repair.

Variables	RV non-reserved (RV strain declined) N = 23	RV reserved (RV strain improved) N = 85	p value
Clinical
Age (y/o)	59.2 ± 12.9	55.7 ± 26.4	0.65
Male (%)	9 (39.1)	38 (44.7)	0.12
Body weight (kg)	58.6 ± 17.7	62.1 ± 10.4	0.71
Body height (cm)	159.6 ± 8.7	161.8 ± 20	0.35
NYFc, n (%)
II	10 (46.1)	38 (44.7)	0.72
III	7 (30.7)	29 (34.1)	0.51
IV	6 (23)	18 (21.2)	0.12
Hypertension, n (%)	9 (39.1)	44 (51.7)	0.09
Diabetes, n (%)	3(13)	10 (11.7)	0.46
CAD, n (%)	3(13)	10 (11.7)	0.65
Af (baseline)	11(47.8)	44 (51.7)	0.52
Creatinine (mg/dl)	0.9 ± 0.2	1.3 ± 1.5	0.34
NT-proBNP (pg/ml)	4938.4 ± 2979.4	4677.1 ± 6998.6	0.3
Surgeries
MV annular ring	19 (82.6)	74 (87.1)	0.52
Repair leaflet
Anterior leaflet	6 (26)	22 (25.8)	0.71
Posterior leaflet	9 (39.1)	34 (40)	0.64
Both leaflets	4 (17.4)	18 (21.2)	0.28
Operation time (hr)	5.4 ± 0.7	5.9 ± 0.9	0.08
Aortic clamping time (min)	103.1 ± 29.3	116 ± 35.5	0.23
CPB time (min)	159 ± 47.3	179.5 ± 47.9	0.16
ICU stay (days)	3.1 ± 2.7	2.8 ± 3.6	0.8
Treatment
β-blocker, n (%)	6 (26)	9 (10.6)	0.67
ACEi/ARB, n (%)	12 (52.2)	22 (25.8)	0.28
Diuretics, n (%)	6 (26)	18 (21.2)	0.28
Anti-coagulants, n (%)	9 (39.1)	18 (21.2)	0.55
Anti-platelet, n (%)	9 (39.1)	34 (40)	0.48
Amiodarone, n (%)	9 (39.1)	20 (23.5)	0.55
Digoxin, n (%)	2 (8.6)	4 (4.7)	0.31

Note: Data are expressed as mean ± SD or number (%). p < 0.05 as significance.

BMI: body mass index; CAD: coronary artery disease; Af: atrial fibrillation; NT-proBNP : NT-pro B-type natriuretic peptite; CPB : cardiopulmonary bypass; ICU: intensive care unit; ACEi/ARB: angiotensin converting enzyme inhibitors/ angiotensin II receptor blocker.